Veru

Veru Days Payable Outstanding

The Days Payable Outstanding (DPO) of Veru (VERU) as of Nov 13, 2026 is 7,490.41. In the previous year, Days Payable Outstanding (DPO) was 100.47 — a change of 7,355.25% (higher).

Days Payable Outstanding

7,490.41

YoY

7,355.25%

Last updated:

Days Payable Outstanding (DPO) of Veru is 2025 7,490.41 . Days Payable Outstanding (DPO) of Veru was 2024 100.47 . It decreases by 7,355.25% higher compared to the previous year.

The Veru Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
166.27 USD
Jan 1, 2019
112.41 USD
Jan 1, 2020
86.96 USD
Jan 1, 2021
93.35 USD
Jan 1, 2022
916.50 USD
Jan 1, 2023
540.59 USD
Jan 1, 2024
100.47 USD
Jan 1, 2025
7,490.41 USD
The Veru Days Payable Outstanding history
YEARDays Payable OutstandingYoY
7,490.41+7,355.25%
100.47-81.41%
540.59-41.02%
916.50+881.79%
93.35+7.34%
86.96-22.63%
112.41-32.39%
166.27+12.56%
147.72+406.75%
29.15+1.08%
28.84-20.14%
36.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veru Stock analysis

What does Veru do? Veru, Inc. generates revenue primarily through its Commercial segment, which focuses on FC2, a female condom product designed to prevent unintended pregnancy and sexually transmitted infections. The company's Research and Development segment develops multiple oncology and urology drug products, including VERU-111, VERU-100, and Zuclomiphene Citrate, targeting prostate cancer and breast cancer. These pipeline products are under clinical development and not yet commercialized. The Commercial segment's FC2 is sold to healthcare providers, distributors, and consumers seeking contraceptive and STI protection solutions. The Research and Development segment's drug candidates are not yet marketed, so revenue from this segment currently comes from partnerships or grants, though the business description does not specify such sources. Veru, Inc. operates in two segments: Commercial and Research and Development. The Commercial segment's FC2 product is the company's sole marketed product, while the Research and Development segment focuses on developing VERU-111, VERU-100, and Zuclomiphene Citrate for prostate cancer and breast cancer treatment. VERU-111 targets microtubules by crosslinking and disrupting alpha and beta tubulin subunits, and VERU-100 is a peptide formulation addressing limitations of androgen deprivation therapies for advanced prostate cancer. Zuclomiphene Citrate is part of the prostate cancer pipeline but lacks further detail in the description. The company's revenue streams are currently limited to FC2 sales in the Commercial segment, with no indication of revenue from the Research and Development segment's pipeline products. FC2 is marketed to healthcare providers, distributors, and end consumers for contraceptive and STI prevention purposes. The business description does not mention any other products, partnerships, or revenue sources beyond FC2 and the R&D pipeline. Veru is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veru stock

Days Payable Outstanding (DPO) of Veru is 7,490.41 in 2025.

Days Payable Outstanding (DPO) of Veru changed from 100.47 to 7,490.41, representing a 7,355.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Veru since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Veru with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Veru

All Key Metrics — Veru